Bio-key

Q2 FY2026 EarningsQ1 FY26 revenue of $2.15M was in-line with the $2.2M consensus, while gross margin significantly beat expectations at 82.5% vs. 76.8% predicted. Normalized EPS of -$0.20 outperformed the -$0.80 consensus, driven by a 24% YoY increase in high-margin license fees and a $98.9k inventory reserve reversal. Despite the bottom-line beat, a 'Going Concern' warning remains due to persistent negative cash flow and Nasdaq delisting risks.